Evidence map›Paper›PMID 41551642›Full record

ArticleProteoglycan research2025

Epithelial Heparan Sulfate Promotes

Kazutaka Hayashida, Jeffrey D Esko, Richard D Gallo, Jian Liu, Winston W-Y Kao, Pyong Woo Park

Abstract read
In one paragraph

Article in Proteoglycan research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Heparan Sulfate Proteoglycans in Immunity.Proteoglycan research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazutaka HayashidaDepartment of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Jeffrey D EskoDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, California, USA.
Richard D GalloDepartment of Dermatology, University of California San Diego, La Jolla, California, USA.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA.
Winston W-Y KaoDepartment of Ophthalmology, University of Cincinnati, Cincinnati, Ohio, USA.
Pyong Woo ParkDepartment of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-7979-4979

Funding

Protein Glycosylation in the Coagulopathy and Inflammation of SepsisP01HL131474 · NHLBI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MAHAN, MICHAEL J · 2016 to 2025
$26.2M
Glypicans in Bacterial Lung InfectionR01HL161605 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Pyong Woo Park · 2024 to 2026
$1.9M
HSPG Interactions in Liver DiseaseR01DK128455 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI PARK, PYONG WOO · 2022 to 2025
$1.8M
ECM Regulation of Ocular Surface DiseaseR01EY033025 · NEI · BOSTON CHILDREN'S HOSPITAL · PI PARK, PYONG WOO · 2022 to 2025
$1.8M
NEI NIH HHS R01 EY033025NHLBI NIH HHS P01 HL131474NHLBI NIH HHS R01 HL161605NIDDK NIH HHS R01 DK128455
6 · The paper itself

Abstract

Cathelicidins are short cationic peptides with potent microbicidal activities and comprise an important arm of host innate immunity. Many cell types can produce cathelicidins, but they are mainly expressed by recruited immune cells and are induced in epithelial cells during infection. Although the mechanisms of bacterial killing by cathelicidins have been largely elucidated in vitro, those that regulate their activities in vivo are less well understood. Bacterial pathogens often co-opt host extracellular matrix (ECM) components and their functions to escape host defense; however, it is unclear whether such mechanisms exist against cathelicidins. Several studies have demonstrated that host heparan sulfate (HS) inhibits LL-37, the human cathelicidin, suggesting that bacteria might exploit HS to evade killing by cathelicidins. However, precisely how HS inhibits LL-37 and possibly other cathelicidins remains unknown, and the role of the HS-cathelicidin interaction in infectious disease has not been rigorously studied. Here, we found that deleting CRAMP, the murine cathelicidin, significantly increases the susceptibility of mice to

Indexed as

antimicrobial peptidecathelicidinglycosaminoglycanheparan sulfatehost defenseStaphylococcus aureus

Identifiers

PMID41551642
PMCPMC12806164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.